Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_30
Snippet: Hyperinflammatory states and cytokine storming, including elevated IL-6, has been reported in severe COVID-19 and were associated with increased mortality in patients in China [36] . A preprint (nonpeer reviewed) case series of 21 patients treated with tocilizumab between February 5 and 14, 2020 in China reported marked success, including rapid resolution of fever and C-reactive protein, decreased oxygen requirements, and resolution of lung opaci.....
Document: Hyperinflammatory states and cytokine storming, including elevated IL-6, has been reported in severe COVID-19 and were associated with increased mortality in patients in China [36] . A preprint (nonpeer reviewed) case series of 21 patients treated with tocilizumab between February 5 and 14, 2020 in China reported marked success, including rapid resolution of fever and C-reactive protein, decreased oxygen requirements, and resolution of lung opacities on computerized tomography imaging [46] . The authors state the patients all had "routine treatment for a week" before tocilizumab, which was described as "standard care according to national treatment guidelines" including lopinavir, methylprednisolone, and other supportive care. All patients had IL-6 analyzed before tocilizumab administration with a mean value of 132.38 ± 278.54 pg/mL (normal <7 pg/mL). It should be noted that in the United States, IL-6 monitoring is a send-out laboratory for most institutions with a turnaround time of 3-7 days. No adverse events were described in the Chinese cohort; however, long-term assessment was not done.
Search related documents:
Co phrase search for related documents- adverse event and increase mortality: 1, 2
- adverse event and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- adverse event and lung opacity: 1
- adverse event and mean value: 1, 2, 3, 4
- adverse event and oxygen requirement: 1, 2, 3, 4, 5
- adverse event and rapid resolution: 1
- adverse event and severe report: 1, 2, 3
- adverse event and standard care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- adverse event and supportive care: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adverse event and treatment guideline: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date